Return to homepagePandemic Pact

A randomised controlled trial comparing antiviral drug favipiravir and a combination of hydroxychloroquine(HCQ) /azithromycin/zinc as interventional treatment for COVID-19 patients with mild to moderate disease

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    Chelsea and Westminster Hospital NHS Foundation Trust, Royal Brompton Hospital, Imperial College

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Chelsea and Westminster Hospital NHS Foundation Trust (Chelsea and Westminster Hospital and West Middlesex University Hospital) has launched a randomised controlled trial to compare two potential treatments for COVID-19 as it first presents in hospital. The two potential treatments were originally the antiviral drug favipiravir and the combination treatment of HCQ/azithromycin/zinc. These treatments have the potential to be used for early intervention through inhibiting the virus's ability to replicate and prevent the diseases progression to the later, more serious phase. However, acting on guidance from the MHRA, the combination treatment arm of HCQ/azithromycin has now been dropped while safety issues around HCQ are being investigated.